(ANSA) – ROME, JUNE 09 – A new drug promises positive effects and an increase in survival against chronic lymphocytic leukemia without worsening the disease. This is what emerges from the final results of the phase III Elevate-Rr study that demonstrated progression-free survival and fewer atrial fibrillation events with the use of acalabrutinib compared to the currently used drug Ibrutinib. “One of the major obstacles to treating patients with chronic lymphocytic leukemia, patients who are typically diagnosed after age 70 and often have one or more comorbidities, is finding effective and tolerated treatment options for long-term disease management without having to interrupt the therapeutic path – explains Paolo Ghia, professor of Medical Oncology at the Vita-Salute San Raffaele University – The results of the Elevate-Rr study confirm the potential of acalabrutinib in terms of disease control for patients with chronic lymphatic leukemia who they have already faced a first line of treatment “. “Having an effective and better tolerated treatment option is excellent news for clinicians and for the more than 3,000 patients in Italy who receive this type of diagnosis every year,” he adds.
Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults, with an estimated 191,000 new cases worldwide. (HANDLE).
REPRODUCTION RESERVED © Copyright ANSA